Migralin (Frovatriptan)

Frovatriptan, the active ingredient in Migralin, is a Triptan (5‑HT1B/1D receptor agonist) presented as an oral tablet for oral use. It is indicated for the acute treatment of migraine attacks in adult patients.

GNH USA supplies Migralin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Frovatriptan belongs to the triptan class and is used to treat migraine attacks by targeting serotonin pathways.

Migraine: provides rapid relief of headache pain, nausea, and photophobia associated with an acute migraine episode. Migraine with aura: reduces the severity and duration of aura symptoms and subsequent headache. Menstrual migraine: offers effective relief when migraine attacks are linked to the menstrual cycle.

Frovatriptan may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Chest discomfort or tightness - Tingling or numbness in the fingers or face - Dizziness or light‑headedness - Fatigue or drowsiness - Nausea or abdominal pain - Dry mouth

Serious or Rare Side Effects: - Coronary vasospasm or myocardial infarction - Severe hypertension or hypertensive crisis - Serotonin syndrome, especially when combined with serotonergic agents - Allergic reactions such as rash, angioedema, or anaphylaxis - Severe skin reactions like Stevens‑Johnson syndrome - Persistent or worsening headache (rebound headache)

Before prescribing Frovatriptan, clinicians should assess cardiovascular risk and consider drug‑specific warnings.

Cardiovascular disease: avoid use in patients with coronary artery disease, uncontrolled hypertension, or history of stroke. Other triptans: do not combine with other triptan medications within 24 hours. Ergot derivatives: avoid concurrent use due to additive vasoconstriction. Serotonergic agents: monitor closely when used with SSRIs, SNRIs, or MAO inhibitors. Pregnancy and lactation: safety not established; use only if benefit outweighs risk. Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Frovatriptan can interact with several drug classes, requiring caution.

Major Interactions (Avoid): - MAO inhibitors: increased risk of serotonin syndrome. - Other triptans: additive vasoconstrictive effects. - Ergot alkaloids: heightened vasospasm risk. - SSRIs/SNRIs: potential for serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP1A2 inhibitors (e.g., fluvoxamine): may raise frovatriptan plasma levels. - Antihypertensive agents: monitor blood pressure for additive effects. - Oral contraceptives: may slightly increase migraine frequency; observe clinical response.